Society 5 min read By Callum Montgomery
Obesity Doctor Urges FDA Crackdown on Compounded GLP-1 Sellers
A leading obesity specialist calls for tighter enforcement against telehealth firms selling compounded weight-loss drugs, warning that patients face unverified ingredients and minimal clinical oversight.
A physician who runs a video-based obesity practice has called on the US Food and Drug Administration to take firmer action against online sellers of compounded GLP-1 weight-loss drugs, arguing that cost pressures are driving patients towards unapproved alternatives with no guaranteed safety or effectiveness.
Writing in a commentary, the obesity specialist said that while telemedicine can safely deliver chronic care, the current market for compounded GLP-1s has become a commercial free-for-all. The drugs are copies of approved medicines such as Wegovy and Ozempic, which are in high demand but often expensive and inconsistently covered by insurance. Compounded versions are marketed as quick, cheap and easy alternatives, yet they are not subject to the same inspections and reviews as commercially manufactured products.
The doctor, who has never prescribed a compounded GLP-1, said the FDA should issue guidance making clear that cost alone is not a medical justification for compounding a drug. The agency should also state that a compounded GLP-1 is not a like-for-like substitute for an approved one, and that prescribing it without genuine medical necessity puts patients at risk and physicians’ licences on the line.
Earlier this year the FDA sent warning letters to 30 telehealth companies that blurred the line between approved and compounded GLP-1s in their advertising. But the specialist argued that vague admonishment does not change commercial behaviour. As demand has surged, so has the market for compounded versions, which can look nearly identical to approved products, with similar names, claims and injector pens.
The risks are not theoretical. Compounded drugs may contain ingredients that have not been tested in combination, and some pharmacies do not follow proper practices or issue certificates of analysis. Sterility failures and dosing errors have become a reality. A patient ordering online through a quick-hit conglomerate has no way of knowing what is in the vial, or whether the label matches the contents.
Medical supervision is also being cut short. The doctor said that before prescribing, a proper assessment should cover a patient’s history of diabetes, sleep apnoea, eating disorders and possible drug interactions. Body composition should be tracked during treatment, because rapid weight loss without enough protein can compromise muscle and bone. A recent study of compounded GLP-1 sellers found next to no clinician involvement, with some orders cleared in under five minutes. That, the specialist said, is commercial fulfilment rather than medical care.
Federal law allows pharmacies to compound for an individual medical need, such as an allergy to an ingredient or an inability to swallow a pill, and to fill temporary gaps during a shortage. When the GLP-1 shortages ended more than a year ago, some sellers pivoted by adding a substance, usually vitamin B12, and marketing the product as personalised. No researcher has studied these combinations in people, and the doctor argued that no reasonable person would consider that type of mass workaround a medical necessity.
The commentary acknowledges why the market exists. These medications are expensive, insurance coverage is inconsistent, and economic strain across the country feels unrelenting. The doctor said these concerns are taken seriously in consultations, but that patients usually arrive at the same conclusion: there is no bargain for medicine when you cannot be sure what you are getting.
Without official intervention, the specialist fears the problem will worsen. An FDA advisory panel last month recommended adding six unapproved peptides to the list of substances that can be compounded in bulk, despite almost no human evidence. Until there is proof that a substance is safe and effective, the doctor will not prescribe it, but warned that without federal requirements some companies will not adhere to the same promise.
The call for enforcement comes as telemedicine expands access to specialists, particularly for chronic conditions. The doctor stressed that a questionnaire is not a physician, and untested, unauthorised lookalikes are not medicines. Doctors have a responsibility to hold that line, and regulators must do the same.
6
